Indaptus Therapeutics Names New CFO, Refreshes Board Oversight

An announcement from Indaptus Therapeutics ( (INDP) ) is now available.

On April 1, 2026, Indaptus Therapeutics announced that Chief Financial Officer Nir Sassi resigned from his role, with the company stating that the departure did not stem from any disagreement over its operations, policies, or practices. That same day, the Board appointed Yu Ding, a veteran financial executive with more than two decades of experience across capital management and public markets in Shanghai and Hong Kong, as the new CFO, signaling a continued emphasis on international capital markets expertise.

Separately, the Board appointed Qinglai Lu to its ranks effective April 8, 2026, determining that he meets Nasdaq’s independence requirements and adding deep Asia-Pacific finance and asset management experience, including work in private credit, fund management and virtual assets. On March 31, 2026, the company also reshaped its Audit Committee, with Matthew McMurdo stepping down and Lu and Chief Executive Officer Jerome Jabbour joining, changes that collectively reflect a broader refresh of Indaptus’s financial governance and oversight framework.

The most recent analyst rating on (INDP) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.

Spark’s Take on INDP Stock

According to Spark, TipRanks’ AI Analyst, INDP is a Neutral.

The score is primarily weighed down by weak financial performance (no revenue, widening losses, and heavy cash burn with a shrinking equity cushion), indicating ongoing financing/dilution risk. Technicals also remain bearish with price below key moving averages and negative MACD. Valuation metrics provide limited support due to negative earnings and no dividend, while recent corporate actions modestly help flexibility but reinforce capital-need concerns.

To see Spark’s full report on INDP stock, click here.

More about Indaptus Therapeutics

Indaptus Therapeutics operates in the biopharmaceutical sector, focusing on the development of novel therapeutics and related clinical-stage assets. The company targets serious diseases with significant unmet medical needs, positioning itself within a competitive market for innovative, science-driven treatments and access to global capital markets.

Average Trading Volume: 58,065

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.59M

Find detailed analytics on INDP stock on TipRanks’ Stock Analysis page.